0.35
-0.0201 (-5.43%)
-0.0201 (-5.43%)
Upgrade to Real-Time
Afterhours (Closed)
Volume | 545,981 |
|
|||||
News | (1) | ||||||
Day High | 0.3799 | Low High |
|||||
Day Low | 0.341 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Marker Therapeutics Inc | MRKR | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
0.361 | 0.341 | 0.3799 | 0.3455 | 0.3701 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
738 | 545,981 | $ 0.3560029 | $ 194,371 | - | 0.25 - 2.05 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:56:15 | formt | 1,108 | $ 0.35 | USD |
Marker Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
$ 29.26M | 83.60M | 58.84M | $ 1.24M | $ - | -0.56 | -0.70 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | $ - | - | 400.00k | 21.70% |
Marker Therapeutics News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MRKR Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.4599 | 0.4599 | 0.341 | 0.3780656 | 582,551 | -0.1099 | -23.9% |
1 Month | 0.3465 | 0.66 | 0.2975 | 0.5193699 | 4,884,757 | 0.0035 | 1.01% |
3 Months | 0.3046 | 0.66 | 0.25 | 0.4993227 | 1,900,338 | 0.0454 | 14.9% |
6 Months | 0.4368 | 0.66 | 0.25 | 0.4820652 | 1,086,080 | -0.0868 | -19.87% |
1 Year | 1.74 | 2.05 | 0.25 | 0.7287201 | 840,402 | -1.39 | -79.89% |
3 Years | 5.61 | 6.54 | 0.25 | 1.93 | 853,867 | -5.26 | -93.76% |
5 Years | 10.01 | 10.25 | 0.25 | 2.42 | 758,173 | -9.66 | -96.5% |
Marker Therapeutics Description
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart. |